泌尿外科

订阅

MedSci主页 / 所有栏目 / 泌尿外科

Eur Urol：前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描成像对前列腺癌是否划算？

2020-12-31 AlexYnag MedSci原创

前列腺癌
关注

在将前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)纳入常规护理之前，评估其效益是重要的。最近，有研究人员确定了PSMA-PET/CT与常规成像相比的效益情况。

在将前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)纳入常规护理之前，评估其效益是重要的。最近，有研究人员确定了PSMA-PET/CT与常规成像相比的效益情况。

研究人员的效益分析包括了proPSMA研究中的数据，其中包括高风险前列腺癌患者，并分配到常规成像或68Ga-PSMA-11 PET/CT，并收集了预先计划的卫生经济学数据。结果表明，PSMA PET/CT每次扫描的估计成本为1203澳元，低于传统成像成本1412澳元。因此，PSMA PET/CT占主导地位，且具有更高的准确性和更低的成本。因此，可节省额外的准确检测结节性疾病的费用959澳元，以及准确检测远处转移的费用1412澳元。这些结果对每次68Ga-PSMA-11运行扫描的男性数量变化最为敏感。需要后续的研究来评估PSMA PET/CT指导护理的长期成本和效益。

最后，研究人员指出，与传统成像相比，PSMA PET/CT对高风险前列腺癌男性的初始分期具有更低的直接比较成本和更高的准确性，为在临床实践中采用PSMA PET/CT提供了一个令人信服的理由。

原始出处：

Rafael E de Feria Cardet ， Michael S Hofman ， Tatiana Segard et al. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer： An Analysis Informed by the proPSMA Trial. Eur Urol. Dec 2020

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1716414, encodeId=16a81e1641408, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Fri May 28 16:49:04 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937604, encodeId=9530193e604f2, content=<a href='/topic/show?id=2f863252123' target=_blank style='color:#2F92EE;'>#前列腺特异性膜抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32521, encryptionId=2f863252123, topicName=前列腺特异性膜抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sun Sep 26 06:49:04 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899446, encodeId=647e1899446e4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 25 01:49:04 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623388, encodeId=660e162338890, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 02 05:49:04 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040915, encodeId=cf9d10409152b, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:49:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-05-28 bioon14

    #计算机#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1716414, encodeId=16a81e1641408, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Fri May 28 16:49:04 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937604, encodeId=9530193e604f2, content=<a href='/topic/show?id=2f863252123' target=_blank style='color:#2F92EE;'>#前列腺特异性膜抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32521, encryptionId=2f863252123, topicName=前列腺特异性膜抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sun Sep 26 06:49:04 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899446, encodeId=647e1899446e4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 25 01:49:04 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623388, encodeId=660e162338890, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 02 05:49:04 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040915, encodeId=cf9d10409152b, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:49:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-09-26 gj0731

    #前列腺特异性膜抗原#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1716414, encodeId=16a81e1641408, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Fri May 28 16:49:04 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937604, encodeId=9530193e604f2, content=<a href='/topic/show?id=2f863252123' target=_blank style='color:#2F92EE;'>#前列腺特异性膜抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32521, encryptionId=2f863252123, topicName=前列腺特异性膜抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sun Sep 26 06:49:04 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899446, encodeId=647e1899446e4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 25 01:49:04 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623388, encodeId=660e162338890, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 02 05:49:04 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040915, encodeId=cf9d10409152b, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:49:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-10-25 jinweidong

    #特异性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1716414, encodeId=16a81e1641408, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Fri May 28 16:49:04 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937604, encodeId=9530193e604f2, content=<a href='/topic/show?id=2f863252123' target=_blank style='color:#2F92EE;'>#前列腺特异性膜抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32521, encryptionId=2f863252123, topicName=前列腺特异性膜抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sun Sep 26 06:49:04 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899446, encodeId=647e1899446e4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 25 01:49:04 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623388, encodeId=660e162338890, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 02 05:49:04 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040915, encodeId=cf9d10409152b, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:49:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-01-02 xiaoyeshuang

    #抗原#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1716414, encodeId=16a81e1641408, content=<a href='/topic/show?id=d68d911542f' target=_blank style='color:#2F92EE;'>#计算机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91154, encryptionId=d68d911542f, topicName=计算机)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def632217870, createdName=bioon14, createdTime=Fri May 28 16:49:04 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937604, encodeId=9530193e604f2, content=<a href='/topic/show?id=2f863252123' target=_blank style='color:#2F92EE;'>#前列腺特异性膜抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32521, encryptionId=2f863252123, topicName=前列腺特异性膜抗原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sun Sep 26 06:49:04 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899446, encodeId=647e1899446e4, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Oct 25 01:49:04 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623388, encodeId=660e162338890, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Jan 02 05:49:04 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040915, encodeId=cf9d10409152b, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:49:04 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-12-31 misszhang

    前列腺癌相关研究，学习了，谢谢梅斯

    0

相关资讯

Eur Urol：传统疗法对前列腺导管癌治疗效果不佳

前列腺导管腺癌（DAC）是一种罕见的、侵袭性的和组织学变异的前列腺癌，用常规疗法治疗，类似于高风险前列腺癌（PAC）。最近，有研究人员评估了接受确定性治疗的DAC或高风险PAC男性的结果，并探索了雄激

Brit J Cancer：PTN可作为前列腺癌转移的生物标志物

从惰性前列腺癌（PC）中区分临床显著前列腺癌是一个重大的临床挑战。

Br J Cancer：LIMK2介导的SPOP磷酸化降解促进去势抵抗性前列腺癌的发生发展

前列腺癌（PCa）目前仍是泌尿外科癌症中最普遍的类型，在美国，其在男性癌症相关死亡中排名第二。2020年美国约有191,930例新病例和33,330例预测死亡病例。尽管雄激素剥夺疗法可以有效治疗该疾病

Eur Urol：中、高风险前列腺癌根治性前列腺切除术中盆腔淋巴结切清扫的扩大与限制比较

扩大盆腔淋巴结切除术（EPLND）在前列腺癌（PCa）患者手术治疗中的作用仍存在争议，主要是因为缺乏随机对照试验（RCTs）。最近，有研究人员确定了是否EPLND与有限制的PLND（LPLND）有更好

Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应

β-放射Lu-177标记的前列腺特异性膜抗原(PSMA)放射配体治疗(RLT)是转移去势抵抗性前列腺癌(mCRPC)的新选择，但其抗肿瘤效果随时间推移而降低。最近，有研究人员报告了&alph

Oncogene：前列腺癌中FRMD6具有抑制肿瘤的功能

现有的前列腺癌（PC）预后工具不是最优的，但可能通过更好地了解驱动肿瘤侵袭性的基因来改善。